Low Grade Glioma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LWG006 MIFTS: 41	Low Grade Glioma Categories: Cancer diseases, Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Low Grade Glioma

MalaCards integrated aliases for Low Grade Glioma:

Name: Low Grade Glioma ¹¹ ¹⁴

Benign Glioma ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0080829

NCIt ⁴⁹ C132067

Sources

Summaries for Low Grade Glioma

Disease Ontology: ¹¹ A cell type benign neoplasm that has material basis in glial cells (astrocytes, oligodendrocytes or ependymocytes).

MalaCards based summary: Low Grade Glioma, also known as benign glioma, is related to glioma susceptibility 1 and oligoastrocytoma. An important gene associated with Low Grade Glioma is KAZALD1 (Kazal Type Serine Peptidase Inhibitor Domain 1), and among its related pathways/superpathways are Disease and Pre-NOTCH Expression and Processing. The drugs Lomustine and Procarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and cortex, and related phenotypes are neoplasm and cellular

Sources

Related Diseases for Low Grade Glioma

Diseases related to Low Grade Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 587)

#	Related Disease	Score	Top Affiliating Genes
1	glioma susceptibility 1	32.8	TP53 MIR21 IDH2 IDH1 H3-3A
2	oligoastrocytoma	32.8	MGMT IDH2
3	glioma	32.7	TP53 NF1 MIR21 MGMT IDH2 IDH1
4	pilocytic astrocytoma	32.5	TP53 SERPINA3 NF1 MGMT KIAA1549 IDH2
5	pleomorphic xanthoastrocytoma	32.3	TP53 SERPINA3 NF1 MGMT KIAA1549 IDH2
6	diffuse astrocytoma	32.2	TP53 SERPINA3 NF1 MGMT KIAA1549 KDM4C
7	oligodendroglioma	31.9	TP53 NF1 MGMT IDH2 IDH1 EGFR
8	neurofibromatosis	31.9	TSC2 TP53 NF1 EGFR
9	neurofibromatosis, type i	31.8	TSC2 TP53 NF1 KIAA1549 IDH1 EGFR
10	high grade glioma	31.6	TP53 MIR9-1 MIR21 MIR155 MIR124-1 MGMT
11	brain cancer	31.5	TP53 NF1 MIR9-1 MIR21 MIR155 MIR139
12	allergic disease	31.3	SERPINA3 MIR21 MIR155 H2AC18
13	ganglioglioma	31.3	TSC2 TP53 NF1 H3-3A
14	glioblastoma	31.3	TSC2 TP53 NF1 MIR21 MIR155 MGMT
15	mixed glioma	31.3	TP53 NF1 MGMT IDH2 IDH1 EGFR
16	fibrillary astrocytoma	31.2	TP53 NF1 KIAA1549 IDH2 IDH1 H3-3B
17	toxic encephalopathy	31.2	TP53 SERPINA3 MIR9-1 MIR124-1 H2AC18
18	meningioma, familial	31.2	TP53 SERPINA3 NF1 MGMT KIAA1549 IDH1
19	central nervous system cancer	31.0	TP53 SERPINA3 MIR9-1 MIR21 MIR155 MIR139
20	gemistocytic astrocytoma	31.0	TP53 MGMT IDH2 IDH1 ATRX
21	brain glioma	30.9	TP53 NF1 MGMT KDM4C IDH2 IDH1
22	neurofibroma	30.9	TP53 NF1 EGFR
23	plexiform neurofibroma	30.8	TP53 NF1 EGFR
24	neuroma	30.8	SERPINA3 NF1 MGMT
25	pituitary gland disease	30.7	MIR9-1 MIR139 H2AC18
26	respiratory failure	30.7	SERPINA3 MIR21 MIR155 H2AC18
27	pilomyxoid astrocytoma	30.7	NF1 MGMT KIAA1549 IDH2 IDH1 H3-3B
28	pilocytic astrocytoma of cerebellum	30.6	NF1 KIAA1549 IDH1 H3-3A
29	rhabdoid cancer	30.6	TP53 MIR9-1 KDM4C H2AC18
30	anaplastic oligodendroglioma	30.6	TP53 NF1 MGMT KIAA1549 KDM4C IDH2
31	focal epilepsy	30.6	MIR9-1 MIR21 MIR139 MIR124-1
32	gliomatosis cerebri	30.6	TP53 MGMT KIAA1549 KDM4C IDH2 IDH1
33	mixed oligodendroglioma-astrocytoma	30.6	TP53 MGMT IDH2 IDH1 ATRX
34	skin melanoma	30.6	TP53 MIR21 KDM4C IDH1 H2AC18
35	psychotic disorder	30.6	SERPINA3 MIR9-1 MIR21 KDM4C H2AC18
36	lung benign neoplasm	30.6	TP53 MGMT EGFR
37	obstructive hydrocephalus	30.5	TSC2 NF1 KIAA1549 H3-3B H3-3A
38	lung squamous cell carcinoma	30.5	TP53 MIR9-1 MIR139 H2AC18 EGFR
39	lymphoma, hodgkin, classic	30.5	TP53 MIR9-1 MIR21 MIR155 KDM4C H2AC18
40	atypical teratoid rhabdoid tumor	30.5	TP53 NF1 MIR124-1 KIAA1549 IDH1 H3-3B
41	melanoma, uveal	30.5	TP53 NF1 MIR9-1 KDM4C H2AC18 EGFR
42	anaplastic astrocytoma	30.5	TP53 SERPINA3 NF1 MGMT KIAA1549 KDM4C
43	bap1 tumor predisposition syndrome	30.5	TSC2 TP53 NF1 EGFR
44	dysembryoplastic neuroepithelial tumor	30.5	NF1 KIAA1549 IDH2 IDH1 H3-3B H3-3A
45	cerebrum cancer	30.5	TP53 MGMT KIAA1549 IDH1 H3-3B H3-3A
46	diffuse midline glioma, h3 k27m-mutant	30.5	TP53 MGMT IDH1 H3-3B H3-3A H2AC18
47	leukemia, acute lymphoblastic	30.5	TP53 MIR9-1 MIR21 MIR155 MIR124-1 KDM4C
48	brain stem glioma	30.5	TP53 KDM4C IDH2 IDH1 H3-3B H3-3A
49	leukemia, chronic myeloid	30.4	TP53 NF1 MIR9-1 MIR155 KDM4C H2AC18
50	leukemia, chronic lymphocytic	30.4	TP53 MIR9-1 MIR21 MIR155 KDM4C H2AC18

Graphical network of the top 20 diseases related to Low Grade Glioma:

Sources

Symptoms & Phenotypes for Low Grade Glioma

MGI Mouse Phenotypes related to Low Grade Glioma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.56	EGFR IDH2 KDM4C MGMT MIR139 NF1
2	cellular	MP:0005384	9.4	ATRX EGFR H3-3A H3-3B IDH2 KDM4C

Sources

Drugs & Therapeutics for Low Grade Glioma

Drugs for Low Grade Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Lomustine

Approved, Investigational

Phase 3

13010-47-4

3950

Procarbazine

Approved, Investigational

Phase 3

671-16-9

4915

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Vincristine

Approved, Investigational

Phase 3

2068-78-2, 57-22-7

5978

Temozolomide

Approved, Investigational

Phase 3

85622-93-1

5394

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Pharmaceutical Solutions

Phase 3

Fluorophosphate

Phase 3

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Vinorelbine

Approved, Investigational

Phase 2

71486-22-1

44424639 60780

Erlotinib

Approved, Investigational

Phase 1, Phase 2

183319-69-9, 183321-74-6

176870

Carmustine

Approved, Investigational

Phase 2

154-93-8

2578

Hydroxyurea

Approved

Phase 2

127-07-1

3657

Dimethyl sulfoxide

Approved, Vet_approved

Phase 1, Phase 2

67-68-5

679

Hydroxychloroquine

Approved

Phase 1, Phase 2

118-42-3

3652

Nivolumab

Approved

Phase 2

946414-94-4

Bevacizumab

Approved, Investigational

Phase 1, Phase 2

216974-75-3

135329020

Irinotecan

Approved, Investigational

Phase 1, Phase 2

97682-44-5, 100286-90-6

60838

Sodium citrate

Approved, Investigational

Phase 1, Phase 2

68-04-2

23431961

Mebendazole

Approved, Vet_approved

Phase 1, Phase 2

31431-39-7

4030

Piperazine

Approved, Vet_approved

Phase 1, Phase 2

110-85-0

4837

Acetaminophen

Approved

Phase 2

103-90-2

1983

Trametinib

Approved

Phase 2

871700-17-3

11707110

Dabrafenib

Approved, Investigational

Phase 2

1195765-45-7

44462760

Olaparib

Approved

Phase 2

763113-22-0

23725625

Everolimus

Approved

Phase 2

159351-69-6

70789204 6442177

Vinblastine

Approved

Phase 2

865-21-4

241903 13342

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 1, Phase 2

77-92-9

311

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

133585-56-5, 60-18-4, 556-02-5

1153 6057

Imatinib Mesylate

Phase 2

220127-57-1

Antirheumatic Agents

Phase 1, Phase 2

Anti-Infective Agents

Phase 1, Phase 2

Antiprotozoal Agents

Phase 1, Phase 2

Antiparasitic Agents

Phase 1, Phase 2

Antimalarials

Phase 1, Phase 2

Antioxidants

Phase 1, Phase 2

Protective Agents

Phase 1, Phase 2

Immune Checkpoint Inhibitors

Phase 2

Antineoplastic Agents, Immunological

Phase 2

topoisomerase I inhibitors

Phase 1, Phase 2

Anthelmintics

Phase 1, Phase 2

Angiogenesis Inhibitors

Phase 1, Phase 2

Anticonvulsants

Phase 1, Phase 2

Citrate

Phase 1, Phase 2

Piperazine citrate

Phase 1, Phase 2

DMP 777

Phase 1, Phase 2

157341-41-8

Interventional clinical trials:

(show top 50) (show all 87)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma	Unknown status	NCT02455245	Phase 3	Carboplatin;Vincristine
2	Ultimate Low Grade Glioma Study	Unknown status	NCT00003015	Phase 3	carboplatin;vincristine sulfate
3	A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma	Completed	NCT00003375	Phase 2, Phase 3	lomustine;procarbazine hydrochloride;vincristine sulfate
4	A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)	Recruiting	NCT04166409	Phase 3	Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
5	A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)	Recruiting	NCT03871257	Phase 3	Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
6	Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery	Recruiting	NCT04316039	Phase 2, Phase 3	Temozolomide
7	A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations	Recruiting	NCT04576117	Phase 3	Selumetinib Sulfate;Vinblastine Sulfate
8	Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma	Recruiting	NCT01649830	Phase 3	Temozolomide
9	Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma	Recruiting	NCT00887146	Phase 3	concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
10	LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy	Not yet recruiting	NCT05566795	Phase 3	DAY101;Chemotherapeutic Agent
11	IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study	Terminated	NCT03763422	Phase 3	Temozolomide
12	Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)	Unknown status	NCT00575796	Phase 2	Vinblastine Sulphate
13	A Phase II Study of Everolimus (RAD001) for Children With Chemotherapy and/or Radiation-Refractory Progressive or Recurrent Low-Grade Gliomas	Completed	NCT00782626	Phase 2	everolimus
14	Phase 2 Study of Weekly Vinorelbine in Children With Progressive or Recurrent Low-Grade Gliomas	Completed	NCT01497860	Phase 2	Vinorelbine
15	Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma	Completed	NCT02197637	Phase 2	ORAL VINORELBINE
16	Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma	Completed	NCT00823459	Phase 2	Everolimus
17	A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma	Completed	NCT00124657	Phase 1, Phase 2	Erlotinib hydrochloride
18	A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Low-grade Glioma	Completed	NCT01635283	Phase 2
19	Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers	Completed	NCT00003467	Phase 2	carmustine;polifeprosan 20 with carmustine implant
20	A Phase II Study of Temozolomide (TEMODAR) in the Treatment of Adult Patients With Supratentorial Low Grade Glioma	Completed	NCT00313729	Phase 2	temozolomide
21	A Phase 2 Study of Vinblastine Sulphate Injection in Children With Recurrent or Refractory Low Grade Glioma	Completed	NCT00213278	Phase 2	vinblastine sulphate injection
22	A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma	Completed	NCT00165360	Phase 2	Temozolomide
23	Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent / Progressive Grade II Low-Grade Glioma	Completed	NCT00615927	Phase 2	Imatinib Mesylate & Hydroxyurea
24	SJ901: Phase 1/2 Evaluation of Single Agent Mirdametinib (PD-0325901), a Brain-Penetrant MEK1/2 Inhibitor, for the Treatment of Children, Adolescents, and Young Adults With Low-Grade Glioma	Recruiting	NCT04923126	Phase 1, Phase 2	Mirdametinib
25	Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults	Recruiting	NCT04201457	Phase 1, Phase 2	Dabrafenib;Trametinib;Hydroxychloroquine
26	FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors	Recruiting	NCT04775485	Phase 2	DAY101
27	Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype	Recruiting	NCT03718767	Phase 2	Nivolumab
28	A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas	Recruiting	NCT01837862	Phase 1, Phase 2	Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
29	A Prospective, Singal-arm Clinical Study of Recombinant Human Endostatin (ENDOSTAR) Combined With Carboplatin and Vincristine in the Treatment of Low-grade Gliomas in Children	Recruiting	NCT04659421	Phase 2	combined therapy with rh-ES and CV
30	Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm	Recruiting	NCT04044937	Phase 2	F-18 Fluoroethyltyrosine (FET)
31	A Phase II Study of Vaccinations With HLA-A2 Restricted Glioma Antigen Peptides in Combination With Poly-ICLC for Children With Recurrent Unresectable Low-Grade Gliomas (LGG)	Recruiting	NCT02358187	Phase 2
32	A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG)	Recruiting	NCT02840409	Phase 2	Vinblastine;Bevacizumab
33	A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1	Recruiting	NCT04544007	Phase 2	Poly ICLC
34	A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma	Active, not recruiting	NCT01089101	Phase 1, Phase 2	Selumetinib
35	A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway.	Active, not recruiting	NCT03363217	Phase 2	Trametinib
36	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes	Active, not recruiting	NCT03233204	Phase 2	Olaparib
37	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex	Active, not recruiting	NCT03213665	Phase 2	Tazemetostat
38	A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation: An Assessment of Long Term Neurocognitive, Neuroendocrine Adn Ototoxicity Outcomes	Active, not recruiting	NCT01288235	Phase 2
39	Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)	Active, not recruiting	NCT02684058	Phase 2	dabrafenib;trametinib;Carboplatin with vincristine
40	PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients With Supratentorial Low-Grade Glioma	Terminated	NCT02023905	Phase 2	Everolimus;Temozolomide
41	Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas	Terminated	NCT01338857	Phase 2	Sorafenib (Nexavar)
42	Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma	Terminated	NCT01887522	Phase 2	Vinblastine + Nilotinib;Vinblastine
43	A Phase 2 Study of the IDH1 Inhibitor, IDH305, for the Treatment of IDH1 Mutated Low Grade Glioma Patients Who Have Measurable 2HG by MR Spectroscopy	Withdrawn	NCT02987010	Phase 2	IDH305
44	Hyperbaric Oxygen Therapy Can Improve Cognitive Deficits Post Low Grade Glioma Removal Surgery - Randomized Prospective Trial	Unknown status	NCT02122042	Phase 1
45	Fluorescence Spectroscopy Guided Surgery for Brain Tumors Resection: a Feasibility Study in Human	Completed	NCT02473380	Phase 1
46	PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA	Completed	NCT01884922	Phase 1	Nilotinib;Vinblastine
47	A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas	Recruiting	NCT03749187	Phase 1	PARP Inhibitor BGB-290;Temozolomide
48	PNOC021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients With Recurrent Low-Grade Gliomas and High Grade Gliomas	Recruiting	NCT04485559	Phase 1	Everolimus;Trametinib
49	A Phase I Study of Tovorafenib/DAY101 (Formerly TAK-580, MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors	Active, not recruiting	NCT03429803	Phase 1	DAY101
50	A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides With Poly-ICLC for Children With Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas	Active, not recruiting	NCT01130077	Phase 1

Search NIH Clinical Center for Low Grade Glioma

Sources

Genetic Tests for Low Grade Glioma

Sources

Anatomical Context for Low Grade Glioma

Organs/tissues related to Low Grade Glioma:

MalaCards : Brain, Temporal Lobe, Cortex, Spinal Cord, Endothelial, Pituitary, Prefrontal Cortex

Sources

Publications for Low Grade Glioma

Articles related to Low Grade Glioma:

(show top 50) (show all 2613)

#	Title	Authors	PMID	Year
1	Incidental low grade glioma in young female: An indolent lesion? A case report and a literature review. ⁶²	Guarracino I...Tomasino B	36410126	2022
2	The relationship between mental fatigue, cognitive functioning, and employment status in patients with low-grade glioma: a cross-sectional single-center study. ⁶²	van Coevorden-van Loon EMP...Ribbers GM	34694184	2022
3	Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. ⁶²	Andersen BM...Reardon DA	36367046	2022
4	Early experience with targeted therapy as a first-line adjuvant treatment for pediatric low-grade glioma. ⁶²	Leclair NK...Hersh DS	36455272	2022
5	Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. ⁶²	Pearson AD...Vassal G	36335782	2022
6	The regulation role and diagnostic value of fibrinogen-like protein 1 revealed by pan-cancer analysis. ⁶²	Yi W...Lv Z	36345363	2022
7	Fluorescein-guided resection for pediatric low-grade gliomas: institutional experience on two cases and a narrative literature review. ⁶²	da Costa MDS...Cavalheiro S	36454311	2022
8	Single-cell RNA sequencing reveals intra-tumoral heterogeneity of glioblastoma and a pro-tumor subset of tumor-associated macrophages characterized by EZH2 overexpression. ⁶²	Chen X...Ding C	36057370	2022
9	Pancancer transcriptomic profiling identifies key PANoptosis markers as therapeutic targets for oncology. ⁶²	Mall R...Kanneganti TD	36329783	2022
10	robustica: customizable robust independent component analysis. ⁶²	Anglada-Girotto M...Head SA	36471244	2022
11	Assessment of structural disconnections in gliomas: comparison of indirect and direct approaches. ⁶²	Silvestri E...Bertoldo A	35503481	2022
12	Molecular subtype classification of low-grade gliomas using magnetic resonance imaging-based radiomics and machine learning. ⁶²	Lam LHT...Le NQK	35767281	2022
13	18 F-FDOPA and MRI Findings in a Case of Multiple Sclerosis. ⁶²	Lersy F...Bund C	35867983	2022
14	Shuffle-ResNet: Deep learning for predicting LGG IDH1 mutation from multicenter anatomical MRI sequences. ⁶²	Safari M...Archambault L	36326618	2022
15	Use of longitudinal functional MRI to demonstrate translocation of language function in patients with brain tumors. ⁶²	Quinones A...Holodny A	36433876	2022
16	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. ⁶²	de Blank PMK...Fisher MJ	35788692	2022
17	Significance of Chr9p22.1-p21.3 Deletion in Cancer Development: A Pan-cancer In Silico Analysis. ⁶²	Goncalves PG...Bidinotto LT	36288884	2022
18	Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations. ⁶²	Mo Z...Wang J	36350002	2022
19	Efficacy of different salvage regimens in progressive unresectable pediatric low-grade glioma. ⁶²	El-Hemaly A...Arafah O	36245827	2022
20	MUC16 mutation is associated with tumor grade, clinical features, and prognosis in glioma patients. ⁶²	Ferrer VP	36436416	2022
21	Association of extent of resection and functional outcomes in diffuse low-grade glioma: systematic review & meta-analysis. ⁶²	Elsheikh M...Poon MTC	36404358	2022
22	Serine hydroxymethyltransferase 1 promotes low-grade glioma progression by activating mTORC1 signaling. ⁶²	Gao Y...Wang Y	36417280	2022
23	Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma. ⁶²	Bouffet E...Fox E	36375115	2022
24	Improved psychotic symptoms following resection of amygdalar low-grade glioma: illustrative case. ⁶²	Andrews JP...Wang DD	36443957	2022
25	Novel TPR::ROS1 Fusion Gene Activates MAPK, PI3K and JAK/STAT Signaling in an Infant-type Pediatric Glioma. ⁶²	Deland L...Abel F	36316040	2022
26	Resection extent and BRAF V600E mutation status determine postoperative tumor growth velocity in pediatric low-grade glioma: results from a single-center cohort analysis. ⁶²	Gorodezki D...Schuhmann MU	36319795	2022
27	Management of epilepsy in brain tumor patients. ⁶²	van der Meer PB...Koekkoek JAF	35838207	2022
28	A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation. ⁶²	Yanchus C...Schramek D	36201590	2022
29	Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients. ⁶²	Miller AM...Karajannis MA	35148412	2022
30	A convolutional neural network model for survival prediction based on prognosis-related cascaded Wx feature selection. ⁶²	Yin Q...Wei Z	35810236	2022
31	Implementing the WHO Global Initiative for Childhood Cancer in Morocco: Survival study for the six indexed childhood cancers. ⁶²	Mechita NB...Hessissen L	35796382	2022
32	Risk factors for early progression of diffuse low-grade glioma in adults. ⁶²	Wang L...Li F	36180935	2022
33	Pediatric spinal pilocytic astrocytomas form a distinct epigenetic subclass from pilocytic astrocytomas of other locations and diffuse leptomeningeal glioneuronal tumours. ⁶²	Metais A...Tauziede-Espariat A	36264505	2022
34	Global survival trends for brain tumours, by histology: analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3). ⁶²	Girardi F...CONCORD Working Group	36215122	2022
35	The need to consider return to work as a main outcome in patients undergoing surgery for diffuse low-grade glioma: a systematic review. ⁶²	Pascual JSG...Duffau H	35945356	2022
36	Sex-Specific Differences in Low-Grade Glioma Presentation and Outcome. ⁶²	Tewari S...Murphy ES	35667529	2022
37	Pan-cancer analysis of GALNTs expression identifies a prognostic of GALNTs feature in low grade glioma. ⁶²	Mao C...Liao J	35075694	2022
38	Is intracranial volume a risk factor for IDH-mutant low-grade glioma? A case-control study. ⁶²	Sagberg LM...Solheim O	36029398	2022
39	Estimating the Prognosis of Low-Grade Glioma with Gene Attention Using Multi-Omics and Multi-Modal Schemes. ⁶²	Choi SR...Lee M	36290366	2022
40	Medical Treatment of Pediatric Low-Grade Glioma. ⁶²	Lim YJ	36347636	2022
41	Weighted correlation network analysis identifies multiple susceptibility loci for low-grade glioma. ⁶²	Niu X...Mao Q	36305248	2022
42	Presurgical predictors of early cognitive outcome after brain tumor resection in glioma patients. ⁶²	Zangrossi A...Corbetta M	36209618	2022
43	Contralesional macrostructural plasticity in patients with frontal low-grade glioma: a voxel-based morphometry study. ⁶²	Lv K...Geng D	36208304	2022
44	A Nationwide Evaluation of Bevacizumab-based Treatments in Paediatric Low-Grade Glioma in the UK: Safety. Efficacy, Visual Morbidity and Outcomes. ⁶²	Green K...Opocher E	36239316	2022
45	Identification of RUNX1 and IFNGR2 as prognostic-related biomarkers correlated with immune infiltration and subtype differentiation of low-grade glioma. ⁶²	Zhang X...Yan X	36321611	2022
46	A Personalized Longitudinal Strategy in Low-Grade Glioma Patients: Predicting Oncological and Neural Interindividual Variability and Its Changes over Years to Think One Step Ahead. ⁶²	Duffau H	36294760	2022
47	[Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers]. ⁶²	Liu J...Wang Y	36305410	2022
48	Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas. ⁶²	Li M...Lin S	35940591	2022
49	Transformed cells after senescence give rise to more severe tumor phenotypes than transformed non-senescent cells. ⁶²	Palazzo A...Bernard D	35926818	2022
50	Language reorganization in patients with left-hemispheric gliomas is associated with increased cortical volume in language-related areas and in the default mode network. ⁶²	Pasquini L...Holodny AI	36356409	2022

Sources

Genes for Low Grade Glioma

Genes related to Low Grade Glioma (0 elite genes):

(show top 50) (show all 60)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	KAZALD1	Kazal Type Serine Peptidase Inhibitor Domain 1	Protein Coding	11.71	DISEASES inferred ¹⁴ GeneCards inferred via : Summaries (show sections)
2	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1	Protein Coding	9.26	DISEASES inferred ¹⁴
3	KIAA1549	KIAA1549	Protein Coding	8.71	DISEASES inferred ¹⁴
4	H2AC18	H2A Clustered Histone 18	Protein Coding	8.65	DISEASES inferred ¹⁴ ¹⁴
5	MIR9-1	MicroRNA 9-1	RNA Gene	8.62	DISEASES inferred ¹⁴ ¹⁴
6	MIR21	MicroRNA 21	RNA Gene	8.46	DISEASES inferred ¹⁴ ¹⁴
7	MGMT	O-6-Methylguanine-DNA Methyltransferase	Protein Coding	8.38	DISEASES inferred ¹⁴
8	KDM4C	Lysine Demethylase 4C	Protein Coding	8.28	DISEASES inferred ¹⁴ ¹⁴
9	IDH2	Isocitrate Dehydrogenase (NADP(+)) 2	Protein Coding	8.28	DISEASES inferred ¹⁴
10	MIR139	MicroRNA 139	RNA Gene	8.23	DISEASES inferred ¹⁴ ¹⁴
11	ATRX	ATRX Chromatin Remodeler	Protein Coding	8.19	DISEASES inferred ¹⁴
12	NF1	Neurofibromin 1	Protein Coding	8.16	DISEASES inferred ¹⁴
13	MIR124-1	MicroRNA 124-1	RNA Gene	8.07	DISEASES inferred ¹⁴ ¹⁴
14	SERPINA3	Serpin Family A Member 3	Protein Coding	7.89	DISEASES inferred ¹⁴ ¹⁴
15	MIR155	MicroRNA 155	RNA Gene	7.82	DISEASES inferred ¹⁴ ¹⁴
16	TP53	Tumor Protein P53	Protein Coding	7.81	DISEASES inferred ¹⁴
17	TSC2	TSC Complex Subunit 2	Protein Coding	7.8	DISEASES inferred ¹⁴
18	EGFR	Epidermal Growth Factor Receptor	Protein Coding	7.69	DISEASES inferred ¹⁴
19	H3-3A	H3.3 Histone A	Protein Coding	7.59	DISEASES inferred ¹⁴
20	H3-3B	H3.3 Histone B	Protein Coding	7.56	DISEASES inferred ¹⁴
21	OLIG2	Oligodendrocyte Transcription Factor 2	Protein Coding	7.5	DISEASES inferred ¹⁴
22	TERT	Telomerase Reverse Transcriptase	Protein Coding	7.49	DISEASES inferred ¹⁴
23	GFAP	Glial Fibrillary Acidic Protein	Protein Coding	7.47	DISEASES inferred ¹⁴
24	TSC1	TSC Complex Subunit 1	Protein Coding	7.45	DISEASES inferred ¹⁴
25	MIR2276	MicroRNA 2276	RNA Gene	7.43	DISEASES inferred ¹⁴ ¹⁴
26	PTEN	Phosphatase And Tensin Homolog	Protein Coding	7.42	DISEASES inferred ¹⁴
27	MIR142	MicroRNA 142	RNA Gene	7.42	DISEASES inferred ¹⁴ ¹⁴
28	MIR106B	MicroRNA 106b	RNA Gene	7.32	DISEASES inferred ¹⁴ ¹⁴
29	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	7.23	DISEASES inferred ¹⁴
30	MIR205	MicroRNA 205	RNA Gene	7.22	DISEASES inferred ¹⁴ ¹⁴
31	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	7.21	DISEASES inferred ¹⁴
32	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	7.17	DISEASES inferred ¹⁴
33	NES	Nestin	Protein Coding	6.99	DISEASES inferred ¹⁴
34	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.96	DISEASES inferred ¹⁴
35	MIR376B	MicroRNA 376b	RNA Gene	6.94	DISEASES inferred ¹⁴ ¹⁴
36	MIR130B	MicroRNA 130b	RNA Gene	6.94	DISEASES inferred ¹⁴ ¹⁴
37	MYBL1	MYB Proto-Oncogene Like 1	Protein Coding	6.93	DISEASES inferred ¹⁴
38	MIR485	MicroRNA 485	RNA Gene	6.92	DISEASES inferred ¹⁴ ¹⁴
39	H3C6	H3 Clustered Histone 6	Protein Coding	6.89	DISEASES inferred ¹⁴
40	H3C3	H3 Clustered Histone 3	Protein Coding	6.89	DISEASES inferred ¹⁴
41	H3C4	H3 Clustered Histone 4	Protein Coding	6.89	DISEASES inferred ¹⁴
42	FGFR1	Fibroblast Growth Factor Receptor 1	Protein Coding	6.82	DISEASES inferred ¹⁴
43	DGCR5	DiGeorge Syndrome Critical Region Gene 5	RNA Gene	6.79	DISEASES inferred ¹⁴ ¹⁴
44	SYP	Synaptophysin	Protein Coding	6.78	DISEASES inferred ¹⁴
45	FUBP1	Far Upstream Element Binding Protein 1	Protein Coding	6.77	DISEASES inferred ¹⁴
46	MIR224	MicroRNA 224	RNA Gene	6.75	DISEASES inferred ¹⁴ ¹⁴
47	MIR330	MicroRNA 330	RNA Gene	6.74	DISEASES inferred ¹⁴ ¹⁴
48	MIR518A1	MicroRNA 518a-1	RNA Gene	6.72	DISEASES inferred ¹⁴ ¹⁴
49	FAM131B	Family With Sequence Similarity 131 Member B	Protein Coding	6.72	DISEASES inferred ¹⁴
50	H3C2	H3 Clustered Histone 2	Protein Coding	6.7	DISEASES inferred ¹⁴

Sources

Variations for Low Grade Glioma

Sources

Expression for Low Grade Glioma

Search GEO for disease gene expression data for Low Grade Glioma.

Sources

Pathways for Low Grade Glioma

Pathways related to Low Grade Glioma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.39	TSC2 TP53 NF1 KIAA1549 IDH1 H3-3B
2	Pre-NOTCH Expression and Processing ⁶⁶ Show member pathways Defective LFNG causes SCDO3 ⁶⁶ Pre-NOTCH Processing in Golgi ⁶⁶ Pre-NOTCH Processing in the Endoplasmic Reticulum ⁶⁶ Pre-NOTCH Transcription and Translation ⁶⁶ Signaling by NOTCH ⁶⁶	12.47	TP53 H3-3B H3-3A H2AC18 EGFR
3	Chromosome Maintenance ⁶⁶ Show member pathways Telomere Maintenance ⁶⁶	12.16	H3-3B H3-3A H2AC18 ATRX
4	Integrated breast cancer pathway ⁷⁴	11.64	TSC2 TP53 NF1 EGFR
5	Head and neck squamous cell carcinoma ⁷⁴	11.47	TSC2 TP53 EGFR
6	miRNAs involvement in the immune response in sepsis ⁷⁴	11.34	MIR9-1 MIR21 MIR155
7	DYRK1A ⁷⁴	11.29	TSC2 TP53 H3-3A
8	Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome ⁷⁴	10.7	TP53 H3-3B H3-3A
9	Transcription_Transcription factor Tubby signaling pathways ²²	10.34	TP53 H3-3B H3-3A EGFR

Sources

GO Terms for Low Grade Glioma

Biological processes related to Low Grade Glioma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of mitophagy	GO:1901525	9.46	TSC2 TP53
2	positive regulation of miRNA maturation	GO:1903800	9.26	TP53 EGFR
3	isocitrate metabolic process	GO:0006102	9.26	IDH2 IDH1
4	glyoxylate cycle	GO:0006097	8.92	IDH2 IDH1

Molecular functions related to Low Grade Glioma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA base-pairing translational repressor activity	GO:1903231	9.46	MIR9-1 MIR21 MIR155 MIR139
2	isocitrate dehydrogenase (NADP+) activity	GO:0004450	9.26	IDH2 IDH1
3	mRNA 3'-UTR binding	GO:0003730	9.1	TP53 MIR9-1 MIR21 MIR155 MIR139